Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Univariate and multivariate Cox regression analysis of the gene signature and disease-free survival of NSCLC patients

From: A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer

Variables Patients
(N)
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
GSE31210
 Age ≤ 65/> 65 176/50 1.89 (1.12–3.18) 1.70E−02 2.36 (1.37–4.04) 1.83E−03
 Gender Female/male 121/105 1.27 (0.78–2.07) 3.38E−01   
 ALK fusion +/− 215/11 0.74 (0.18–3.02) 6.73E−01   
 EGFR mutation +/− 99/127 0.60 (0.37–0.98) 4.29E−02 1.98 (0.88–4.47) 1.00E−01
 KRAS mutation +/− 206/20 0.98 (0.42–2.26) 9.56E−01   
 Triple negative No/yes 158/68 1.87 (1.14–3.08) 1.39E−02 2.91 (1.30–6.54) 9.71E−03
 Myc copy Low/high 207/17 1.04 (0.42–2.59) 9.33E−01   
 Stage I/II 168/58 3.16 (1.92–5.21) 6.09E−06 2.77 (1.63–4.71) 1.62E−04
 Smoking No/yes 115/111 1.33 (0.82–2.18) 2.52E−01   
 Risk score Low/high 123/103 3.26 (1.92–5.53) 1.24E−05 3.10 (1.77–5.41) 7.17E−05
GSE37745
 Age ≤ 65/> 65 45/51 0.89 (0.50–1.55) 6.70E−01   
 Gender Female/male 46/50 1.01 (0.58–1.78) 9.60E−01   
 Stage I/II 63/18 1.13 (0.54–2.38) 7.45E−01   
 Stage I/III 63/14 1.78 (0.81–3.91) 1.48E−01   
 Stage I/IV 63/1 5.71 (0.75–43.63) 9.32E−02   
 Histological type Adeno/large 53/13 1.05 (0.46–2.42) 9.08E−01   
 Histological type Adeno/squamous 53/30 1.12 (0.60–2.10) 7.17E−01   
 WHO performance status 0/1 54/32 2.21 (1.21–4.03) 1.02E−02 2.43 (1.32–4.47) 4.31E−03
 WHO performance status 0/2 54/6 1.04 (0.25–4.42) 9.52E−01 1.12 (0.26–4.75) 8.77E−01
 WHO performance status 0/3 54/4 1.66 (0.50–5.53) 4.08E−01 1.62 (0.49–5.38) 4.34E−01
 Risk score Low/high 46/50 2.31 (1.27–4.21) 6.08E−03 2.49 (1.36–4.55) 3.10E−03
GSE50081
 Age ≤ 65/> 65 59/118 1.24 (0.69–2.24) 4.77E−01   
 Gender Female/male 81/96 1.68 (0.95–2.99) 7.59E−02   
 Stage I/II 124/53 1.87 (1.06–3.28) 3.03E−02 1.71 (0.97–3.01) 6.30E−02
 Histological type Adeno/large 124/7 1.04 (0.25–4.31) 9.59E−01   
 Histological type Adeno/squamous 124/42 0.73 (0.10–5.36) 7.61E−01   
 Histological type Adeno/other 124/4 0.74 (0.38–1.45) 3.79E−01   
 Smoking No/yes 24/133 0.70 (0.35–1.40) 3.14E−01   
 Risk score Low/high 83/94 2.42 (1.33–4.43) 4.02E−03 2.30 (1.26–4.22) 6.97E−03
All patients
 Age ≤ 65/> 65 280/219 1.36 (1.00–1.84) 5.04E−02   
 Gender Female/male 248/251 1.31 (0.96–1.78) 8.51E−02   
 Stage I/II 355/129 2.05 (1.47–2.85) 2.02E−05 1.72 (1.23–2.40) 1.50E−03
 Stage I/III 355/14 3.45 (1.68–7.11) 7.74E−04 2.62 (1.27–5.43) 9.41E−03
 Stage I/IV 355/1 22.26 (3.01–164.44) 2.36E−03 14.79 (2.00–109.7) 8.40E−03
 Histological type Adeno/large 403/20 1.48 (0.75–2.93) 2.61E−01   
 Histological type Adeno/squamous 403/72 0.76 (0.11–5.44) 7.85E−01   
 Histological type Adeno/other 403/4 1.17 (0.77–1.78) 4.52E−01   
 Risk score Low/high 252/247 2.7 (1.94–3.76) 4.16E−09 2.39 (1.70–3.35) 4.47E−07
  1. HR: hazard ratio; CI: confidence interval; Adeno: adenocarcinoma; Large: large cell carcinoma; Squamous: squamous cell carcinoma